Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Studies point to redlining as a 'perfect storm' for breast cancer

2.

Combo of Approved Agents Active in High-Risk Large B-Cell Lymphoma

3.

Many Americans unaware of links between HPV and cancers, poll reveals

4.

FDA Approves Hemophilia B Second Gene Therapy.

5.

In advanced endometrial cancer, immunocheckpoint inhibitor-chemotherapy combination improves overall survival.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot